Connect With Us
Resources and Links
- Blackboard/WebCT Login
- College Catalog
- Drug Information Resources
- Experiential Education
- Honors Program
- Library/Learning Resources
- Research Opportunities for CPPS Students
- Student Affairs
- Student Organizations
Main and Health Science CampusesWolfe Hall 1227 (MC)
Frederic and Mary Wolfe Center 155 (HSC)
Phone: 419.383.1904 email@example.com
Medicinal and Biological Chemistry
Katherine A. Wall, Ph.D.
Professor and Chair, Department of Medicinal and Biological Chemistry
|B.S., 1971||Montana State University|
|Ph.D., 1977||University of California at Berkeley|
|Damon Runyon-Walter Winchell
Cancer Research Fellowship
|Massachusetts Institute of Technology|
|NIH Fellowship, 1980-82||University of Chicago|
|Visiting Investigator 2000-01||University of Michigan|
|Visiting Professor 2010||University of Rochester Medical Center|
Immunology and biochemistry; molecular analysis of the autoimmune disease myasthenia gravis using a murine model system; design of immunomodulatory drugs.
I have three major projects ongoing in my laboratory.
1) Cytokines in Myasthenia Gravis
Myasthenia gravis is an autoimmune disease characterized by autoantibodies to the nicotinic acetylcholine receptor. Over the past 20 years, my collaborators and I have defined the T cell response to the acetylcholine receptor in a murine model of myasthenia gravis, experimental autoimmune myasthenia gravis (EAMG). Currently we seek to determine the mechanisms by which factors other than antibody titer affect disease severity in myasthenia gravis. We are studying the role of the cytokine interleukin 12 (IL-12) in enhancing passive transfer of EAMG. We have shown that interferon gamma is important in enhancing disease and are determining the source of interferon gamma and its effects on muscle tissue
2) Glycopeptide-Based Cancer Antigen Vaccines
This project is a collaboration with Dr. Steve Sucheck of the UT Dept. of Chemistry. We have been studying the immune response of mice to cancer vaccines containing synthetic cancer glycopeptide antigens with a covalently attached rhamnose epitope. This is designed to take advantage of anti-rhamnose antibodies that occur naturally in humans and can be generated in mice. We are developing additional synthetic vaccines that take advantage of antibody targeting.
3) CD38 and NAD Metabolites in Lymphocyte Signaling
I have a longstanding interest in the role of NAD metabolites in lymphocyte function. During a sabbatical with Dr. Frances Lund in Rochester, NY in 2010, I began a study of CD38 and NAD metabolites in T cell function. My lab is continuing a collaboration with Dr. James Slama to examine the role of NAADP, a newly discovered calcium mobilizing agent, in lymphocyte signaling and function.
1. Activity of nicotinic acid substituted nicotinic acid adenine dinucleotide phosphate (NAADP) analogs in a human cell line: difference in specificity between human and sea urchin NAADP receptors. R. A. Ali, T. Zhelay, C. Trabbic, T. F. Walseth, J. T. Slama, D. R. Giovannucci, and K. A. Wall. Cell Calcium 55: 93– 103, 2014. PUBMED/24439527
2. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into L-rhamnose displaying liposomes. S. Sarkar, A. Salyer, K. A. Wall, and S. Sucheck. Bioconjugate Chem. 24: 363–375, 2013. PUBMED/23444835
3. Synthesis of a single molecule L-rhamnose-containing three component vaccine and evaluation of antigenicity in the presence of anti-L-rhamnose antibodies. S. Sarkar, S. A. Lombardo, D. N. Herner, R. S. Talan, K. A. Wall, and S. J. Sucheck. J. Amer. Chem. Soc. 132. 17236-17246, 2010. PUBMED/21080675
4. Cowpea mosaic virus capsid: a promising carrier for the development of carbohydrate based antitumor vaccines. A. Miermont, H. Barnhill, E. Strable, X. Lu, K. A. Wall, Q. Wang, M. G. Finn, and X. Huang. Chemistry - A European Journal 14: 4939-4947, 2008. PUBMED/18431733
5. Recall immune memory: A new tool for generating late onset autoimmune myasthenia
gravis. S. Stacy, A. J. Infante, K. A. Wall, K. Krolick, and E. Kraig. Mechanisms of Ageing and Development 124: 931-940, 2003. PUBMED/14499498
6. Split tolerance in a novel transgenic model of autoimmune myasthenia gravis. S. Stacy, B. Gelb, B. A. Koop, J. J. Windle, K. A. Wall, K. A. Krolick, A. J. Infante, and E. Kraig. J. Immunol. 169: 6570-6579, 2002. PUBMED/12444169
7. Interleukin-12 enhances clinical experimental autoimmune myasthenia gravis in susceptible but not resistant mice. S. Sitaraman, D. W. Metzger, R. J. Belloto, Jr., A. J. Infante, and K. A. Wall. J. Neuroimmunol. 107: 73-82, 2000. PUBMED/10808053